Submitted by Anonymous (not verified) on 5 December 2025 - 8:37
Opinion/decision on a Paediatric investigation plan (PIP): Ilumetri, tildrakizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Skin and subcutaneous tissue disorders, PIP number: EMA/PE/0000182362
Source: